Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcadia Biosciences (RKDA) Liabilities from Discontinued Operations (2022 - 2024)

Arcadia Biosciences (RKDA) has disclosed Liabilities from Discontinued Operations for 3 consecutive years, with 240000.0 as the latest value for Q2 2024.

  • For the quarter ending Q2 2024, Liabilities from Discontinued Operations changed N/A year-over-year to 240000.0, compared with a TTM value of 240000.0 through Jun 2024, changed N/A, and an annual FY2023 reading of 500000.0, up 1823.08% over the prior year.
  • Liabilities from Discontinued Operations was 240000.0 for Q2 2024 at Arcadia Biosciences, down from 500000.0 in the prior quarter.
  • Across five years, Liabilities from Discontinued Operations topped out at 500000.0 in Q4 2023 and bottomed at 26000.0 in Q4 2022.
  • Average Liabilities from Discontinued Operations over 3 years is 199250.0, with a median of 135500.0 recorded in 2023.
  • Peak annual rise in Liabilities from Discontinued Operations hit 1823.08% in 2023, while the deepest fall reached 1823.08% in 2023.
  • Year by year, Liabilities from Discontinued Operations stood at 26000.0 in 2022, then surged by 1823.08% to 500000.0 in 2023, then tumbled by 52.0% to 240000.0 in 2024.
  • Business Quant data shows Liabilities from Discontinued Operations for RKDA at 240000.0 in Q2 2024, 500000.0 in Q4 2023, and 31000.0 in Q3 2023.